Evidence map›Paper›PMID 29942011›Full record

ArticleScientific reports2018

Development of an optimal imaging strategy for selection of patients for affibody-based PNA-mediated radionuclide therapy.

Anzhelika Vorobyeva, Kristina Westerlund, Bogdan Mitran, Mohamed Altai, Sara Rinne, Jens Sörensen, Anna Orlova, Vladimir Tolmachev, Amelie Eriksson Karlström

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Anzhelika VorobyevaDepartment of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.ORCID 0000-0002-4778-3909
Kristina WesterlundDepartment of Protein Science, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, Stockholm, Sweden.
Bogdan MitranDepartment of Medicinal Chemistry, Uppsala University, Uppsala, Sweden.
Mohamed AltaiDepartment of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Sara RinneDepartment of Medicinal Chemistry, Uppsala University, Uppsala, Sweden.
Jens SörensenNuclear Medicine and PET, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
Anna OrlovaDepartment of Medicinal Chemistry, Uppsala University, Uppsala, Sweden.
Vladimir TolmachevDepartment of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden. vladimir.tolmachev@igp.uu.se.ORCID 0000-0002-6122-1734
Amelie Eriksson KarlströmDepartment of Protein Science, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, Stockholm, Sweden.
Uppsala University · SEKTH Royal Institute of Technology · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Affibody molecules are engineered scaffold proteins, which demonstrated excellent binding to selected tumor-associated molecular abnormalities in vivo and highly sensitive and specific radionuclide imaging of Her2-expressing tumors in clinics. Recently, we have shown that peptide nucleic acid (PNA)-mediated affibody-based pretargeted radionuclide therapy using beta-emitting radionuclide

Indexed as

Patient SelectionRadiotherapyRecombinant Fusion ProteinsAnimalsCell Line, TumorCell Transformation, NeoplasticErb-b2 Receptor Tyrosine KinasesFemaleIsotope LabelingMicePeptide Nucleic AcidsPositron Emission Tomography Computed Tomographyaffibody (ZHER2-342)2ERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesPeptide Nucleic AcidsRecombinant Fusion Proteins

Identifiers

PMID29942011
PMCPMC6018533
OpenAlexW2809396651

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.